A detailed history of Israel Englander (Millennium Management LLC) transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 3,621,670 shares of ACET stock, worth $4.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,621,670
Previous 4,106,170 11.8%
Holding current value
$4.71 Million
Previous $9.65 Million 54.59%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.21 - $2.4 $586,245 - $1.16 Million
-484,500 Reduced 11.8%
3,621,670 $4.38 Million
Q1 2024

May 15, 2024

BUY
$1.76 - $3.45 $4.9 Million - $9.61 Million
2,784,583 Added 210.7%
4,106,170 $9.65 Million
Q4 2023

Feb 14, 2024

BUY
$1.11 - $1.89 $601,517 - $1.02 Million
541,908 Added 69.5%
1,321,587 $2.5 Million
Q2 2023

Aug 14, 2023

BUY
$2.13 - $7.13 $1.3 Million - $4.34 Million
608,803 Added 356.28%
779,679 $1.89 Million
Q1 2023

May 15, 2023

BUY
$5.52 - $9.23 $521,579 - $872,133
94,489 Added 123.7%
170,876 $984,000
Q4 2022

Feb 14, 2023

BUY
$7.72 - $21.27 $589,707 - $1.62 Million
76,387 New
76,387 $683,000
Q2 2022

Aug 15, 2022

BUY
$10.26 - $20.81 $1.32 Million - $2.68 Million
128,666 New
128,666 $1.88 Million
Q4 2021

Feb 14, 2022

SELL
$7.37 - $17.49 $167,645 - $397,845
-22,747 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$6.29 - $9.93 $456,685 - $720,967
-72,605 Reduced 76.14%
22,747 $178,000
Q2 2021

Aug 16, 2021

SELL
$9.19 - $15.93 $778,291 - $1.35 Million
-84,689 Reduced 47.04%
95,352 $981,000
Q1 2021

May 17, 2021

BUY
$12.12 - $17.17 $1.91 Million - $2.71 Million
157,963 Added 715.48%
180,041 $2.36 Million
Q4 2020

Feb 16, 2021

BUY
$10.36 - $14.77 $228,728 - $326,092
22,078 New
22,078 $310,000

Others Institutions Holding ACET

About Adicet Bio, Inc.


  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $52M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.